Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.
- DOI
- 10.1007/s10637-022-01315-6
- Published
- 2023 Apr
- Container
- Investigational new drugs
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10637-022-01315-6,
title = {Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.},
author = {Nguyen CN and Iyer SP and Duvic M and Barde PJ and Nair A and Routhu KV and Huen AO},
year = {2023},
journal = {Investigational new drugs},
doi = {10.1007/s10637-022-01315-6},
url = {https://doi.org/10.1007/s10637-022-01315-6}
}RIS
TY - JOUR TI - Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome. AU - Nguyen CN AU - Iyer SP AU - Duvic M AU - Barde PJ AU - Nair A AU - Routhu KV AU - Huen AO PY - 2023 JO - Investigational new drugs DO - 10.1007/s10637-022-01315-6 UR - https://doi.org/10.1007/s10637-022-01315-6 ER -
APA
CN, N., SP, I., M, D., PJ, B., A, N., KV, R., & AO, H. (2023). Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.. Investigational new drugs. https://doi.org/10.1007/s10637-022-01315-6
Source records
- pubmed · retrieved 2026-09-26T12:30:34.071Z
- europe-pmc · retrieved 2026-09-26T12:30:34.061Z